Milind Deshpande

Achillion Pharmaceuticals

Former Director and Chief Executive Officer

Overview

Milind Deshpande made an average of $2M in compensation at Achillion Pharmaceuticals from 2008 to 2018.

Annual data

2018

In 2018, Milind Deshpande earned a total compensation of $2.1M as Former Director and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking4,544 out of 10,934
Percentile58.4%

Milind Deshpande's 2018 compensation ranked 4,544th out of 10,934 executive pay records tracked by us this year.

Deshpande earned more than 58.4% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking499 out of 1,246
Percentile60.0%

In the industry group of Drugs, Deshpande's pay ranked 499th out of 1,246 executive pay records tracked by us in 2018.

Deshpande earned more than 60.0% of executives in this group.

Option Awards$1,295,616
Salary$227,888
Other$545,959
Total$2,069,463

Deshpande received $1.3M in option awards, which accounts for 62.61% of total compensation.

Deshpande also received $227.9K in salary and $546K in other compensation.

2017

In 2017, Milind Deshpande earned a total compensation of $2.2M as Former Director and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking4,750 out of 13,778
Percentile65.5%

Milind Deshpande's 2017 compensation ranked 4,750th out of 13,778 executive pay records tracked by us this year.

Deshpande earned more than 65.5% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking376 out of 1,566
Percentile76.0%

In the industry group of Drugs, Deshpande's pay ranked 376th out of 1,566 executive pay records tracked by us in 2017.

Deshpande earned more than 76.0% of executives in this group.

Non-Equity Incentive Plan$260,703
Option Awards$1,335,258
Salary$607,700
Other$8,557
Total$2,212,218

Deshpande received $1.3M in option awards, which accounts for 60.36% of total compensation.

Deshpande also received $260.7K in non-equity incentive plan, $607.7K in salary and $8.6K in other compensation.

2016

In 2016, Milind Deshpande earned a total compensation of $3M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking3,226 out of 14,038
Percentile77.0%

Milind Deshpande's 2016 compensation ranked 3,226th out of 14,038 executive pay records tracked by us this year.

Deshpande earned more than 77.0% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking233 out of 1,500
Percentile84.5%

In the industry group of Drugs, Deshpande's pay ranked 233rd out of 1,500 executive pay records tracked by us in 2016.

Deshpande earned more than 84.5% of executives in this group.

Non-Equity Incentive Plan$218,144
Option Awards$2,153,727
Salary$590,000
Other$8,310
Total$2,970,181

Deshpande received $2.2M in option awards, which accounts for 72.51% of total compensation.

Deshpande also received $218.1K in non-equity incentive plan, $590K in salary and $8.3K in other compensation.

2015

In 2015, Milind Deshpande earned a total compensation of $950.1K as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking8,198 out of 13,589
Percentile39.7%

Milind Deshpande's 2015 compensation ranked 8,198th out of 13,589 executive pay records tracked by us this year.

Deshpande earned more than 39.7% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking897 out of 1,485
Percentile39.6%

In the industry group of Drugs, Deshpande's pay ranked 897th out of 1,485 executive pay records tracked by us in 2015.

Deshpande earned more than 39.6% of executives in this group.

Non-Equity Incentive Plan$416,667
Salary$525,100
Other$8,298
Total$950,065

Deshpande received $525.1K in salary, which accounts for 55.27% of total compensation.

Deshpande also received $416.7K in non-equity incentive plan and $8.3K in other compensation.

2014

In 2014, Milind Deshpande earned a total compensation of $4.9M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking1,584 out of 12,932
Percentile87.8%

Milind Deshpande's 2014 compensation ranked 1,584th out of 12,932 executive pay records tracked by us this year.

Deshpande earned more than 87.8% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking138 out of 1,316
Percentile89.5%

In the industry group of Drugs, Deshpande's pay ranked 138th out of 1,316 executive pay records tracked by us in 2014.

Deshpande earned more than 89.5% of executives in this group.

Non-Equity Incentive Plan$384,860
Option Awards$4,070,653
Salary$484,100
Other$8,124
Total$4,947,737

Deshpande received $4.1M in option awards, which accounts for 82.27% of total compensation.

Deshpande also received $384.9K in non-equity incentive plan, $484.1K in salary and $8.1K in other compensation.

2013

In 2013, Milind Deshpande earned a total compensation of $4.3M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking1,572 out of 12,071
Percentile87.0%

Milind Deshpande's 2013 compensation ranked 1,572nd out of 12,071 executive pay records tracked by us this year.

Deshpande earned more than 87.0% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking93 out of 1,102
Percentile91.6%

In the industry group of Drugs, Deshpande's pay ranked 93rd out of 1,102 executive pay records tracked by us in 2013.

Deshpande earned more than 91.6% of executives in this group.

Non-Equity Incentive Plan$148,893
Option Awards$3,679,998
Salary$435,583
Other$7,992
Total$4,272,466

Deshpande received $3.7M in option awards, which accounts for 86.13% of total compensation.

Deshpande also received $148.9K in non-equity incentive plan, $435.6K in salary and $8K in other compensation.

2012

In 2012, Milind Deshpande earned a total compensation of $1.5M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking4,481 out of 11,148
Percentile59.8%

Milind Deshpande's 2012 compensation ranked 4,481st out of 11,148 executive pay records tracked by us this year.

Deshpande earned more than 59.8% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking222 out of 863
Percentile74.3%

In the industry group of Drugs, Deshpande's pay ranked 222nd out of 863 executive pay records tracked by us in 2012.

Deshpande earned more than 74.3% of executives in this group.

Non-Equity Incentive Plan$201,272
Option Awards$922,084
Salary$376,100
Other$7,833
Total$1,507,289

Deshpande received $922.1K in option awards, which accounts for 61.17% of total compensation.

Deshpande also received $201.3K in non-equity incentive plan, $376.1K in salary and $7.8K in other compensation.

2011

In 2011, Milind Deshpande earned a total compensation of $1.1M as Director, President and Chief Executive Officer at Achillion Pharmaceuticals.

Ranking5,281 out of 10,255
Percentile48.5%

Milind Deshpande's 2011 compensation ranked 5,281st out of 10,255 executive pay records tracked by us this year.

Deshpande earned more than 48.5% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking260 out of 716
Percentile63.7%

In the industry group of Drugs, Deshpande's pay ranked 260th out of 716 executive pay records tracked by us in 2011.

Deshpande earned more than 63.7% of executives in this group.

Non-Equity Incentive Plan$144,536
Option Awards$555,511
Salary$359,975
Other$7,703
Total$1,067,725

Deshpande received $555.5K in option awards, which accounts for 52.03% of total compensation.

Deshpande also received $144.5K in non-equity incentive plan, $360K in salary and $7.7K in other compensation.

2010

In 2010, Milind Deshpande earned a total compensation of $907.1K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking5,430 out of 9,770
Percentile44.4%

Milind Deshpande's 2010 compensation ranked 5,430th out of 9,770 executive pay records tracked by us this year.

Deshpande earned more than 44.4% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking259 out of 636
Percentile59.3%

In the industry group of Drugs, Deshpande's pay ranked 259th out of 636 executive pay records tracked by us in 2010.

Deshpande earned more than 59.3% of executives in this group.

Non-Equity Incentive Plan$116,000
Option Awards$454,000
Salary$329,436
Other$7,673
Total$907,109

Deshpande received $454K in option awards, which accounts for 50.05% of total compensation.

Deshpande also received $116K in non-equity incentive plan, $329.4K in salary and $7.7K in other compensation.

2009

In 2009, Milind Deshpande earned a total compensation of $540K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking6,187 out of 9,044
Percentile31.6%

Milind Deshpande's 2009 compensation ranked 6,187th out of 9,044 executive pay records tracked by us this year.

Deshpande earned more than 31.6% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking349 out of 593
Percentile41.1%

In the industry group of Drugs, Deshpande's pay ranked 349th out of 593 executive pay records tracked by us in 2009.

Deshpande earned more than 41.1% of executives in this group.

Non-Equity Incentive Plan$90,957
Option Awards$141,000
Salary$303,190
Other$4,841
Total$539,988

Deshpande received $303.2K in salary, which accounts for 56.15% of total compensation.

Deshpande also received $91K in non-equity incentive plan, $141K in option awards and $4.8K in other compensation.

2008

In 2008, Milind Deshpande earned a total compensation of $410.3K as President, Research and Development and Chief Scientific Officer at Achillion Pharmaceuticals.

Ranking6,455 out of 8,153
Percentile20.8%

Milind Deshpande's 2008 compensation ranked 6,455th out of 8,153 executive pay records tracked by us this year.

Deshpande earned more than 20.8% of all executives tracked by us in 2018.

Industry groupDrugs
Ranking401 out of 555
Percentile27.7%

In the industry group of Drugs, Deshpande's pay ranked 401st out of 555 executive pay records tracked by us in 2008.

Deshpande earned more than 27.7% of executives in this group.

Non-Equity Incentive Plan$51,975
Option Awards$61,357
Salary$288,000
Other$8,921
Total$410,253

Deshpande received $288K in salary, which accounts for 70.20% of total compensation.

Deshpande also received $52K in non-equity incentive plan, $61.4K in option awards and $8.9K in other compensation.